A single institutional comparison between PSMA PET and fluciclovine PET in prostate cancer patients with biochemical recurrence after radical prostatectomy (PSA <2.0 ng/mL) found that, in 50 enrolled patients, detection rates were lower with fluciclovine PET (13 of 50, 26%) versus PSMA PET (28 of 50, 56%), with an odds ratio of 4.8 at the patient level (95% CI 1.6-19.2, p=0.0026) (24). The gene discussed is KLK3; the disease is prostate carcinoma.